Skip to main content

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business

Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation RD business, bigger than most of its peers, developing a potential pipeline of drug assets

from Moneycontrol Business News https://ift.tt/3i62RHe

Comments

Popular posts from this blog

German cabinet to hold secret session on Huawei#39;s role in 5G network: Report

Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology for spying, which the company denies. from Moneycontrol Business News http://bit.ly/2TyXzFb

Infosys partners Avaloq to strengthen wealth management capabilities via digital platforms

Infosys will be a strategic implementation partner for Avaloq#39;s wealth management suite of solutions to help clients modernize and transform their legacy systems into cutting-edge digital advisory platforms, a statement said. from Moneycontrol Business News https://ift.tt/2THaSpn